Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL5699197 | 1.00 | — | — | |
| Iodide SCHEMBL28859824 | 0.95 | — | — | |
| SCHEMBL21311 | 0.94 | — | — | |
| Ammonia Solution, Strong SCHEMBL902203 | 0.89 | — | — | |
| Ammonia Solution, Strong SCHEMBL7559311 | 0.89 | — | — | |
| SCHEMBL3310527 | 0.89 | — | — | |
| SCHEMBL6561320 | 0.89 | — | — | |
| SCHEMBL1291829 | 0.84 | — | — | |
| SCHEMBL8649499 | 0.84 | — | — | |
| Ammonia Solution, Strong SCHEMBL8109014 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999025385-A1 | A METHOD OF INCREASING NUCLEIC ACID SYNTHESIS WITH ULTRASOUND | IMARX PHARMACEUTICAL CORP. (US) | 1999-05-27 | — | — | WO | claimed |
| US-12590322-B2 | Devices and methods for mitochondria replacement and for generating cellular therapeutics | NanoCav, LLC (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2025076338-A1 | NANOBUBBLES FOR ULTRASOUND MEDIATED NUCLEIC ACID DELIVERY | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230304043-A1 | Devices And Methods For Mitochondria Replacement And For Generating Cellular Therapeutics | NanoCav, LLC | 2023-09-28 | — | — | US | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11639510-B2 | Devices and methods for mitochondria replacement and for generating cellular therapeutics | NanoCav, LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11453701-B2 | Tau aggregation peptide inhibitors | ADRX, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220226484-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-108884137-B | Peptides and their use in treating diseases, disorders, or conditions associated with mutant p53 | 耶达研究及发展有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11230578-B2 | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53 | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
| CN-105579464-A | Peptides capable of reactivating p53 mutants | YEDA RES & DEV | 2016-05-11 | — | — | CN | disclosed |
| CN-1082043-C | Novel cationic lipids and the use thereof | IMARX PHARMACEUTICAL CORP (US) | 2002-04-03 | — | — | CN | disclosed |
| CN-1177342-A | Novel cationic lipids and the use thereof | IMAR PHARMACEUTICAL CORP (US) | 1998-03-25 | — | — | CN | disclosed |